688 related articles for article (PubMed ID: 23413807)
1. Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis.
Lipowicz S; Sekula P; Ingen-Housz-Oro S; Liss Y; Sassolas B; Dunant A; Roujeau JC; Mockenhaupt M
Br J Dermatol; 2013 Apr; 168(4):726-32. PubMed ID: 23413807
[TBL] [Abstract][Full Text] [Related]
2. Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features.
Cho YT; Lin JW; Chen YC; Chang CY; Hsiao CH; Chung WH; Chu CY
J Am Acad Dermatol; 2014 Mar; 70(3):539-48. PubMed ID: 24388722
[TBL] [Abstract][Full Text] [Related]
3. The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies.
Lee HY; Dunant A; Sekula P; Mockenhaupt M; Wolkenstein P; Valeyrie-Allanore L; Naldi L; Halevy S; Roujeau JC
Br J Dermatol; 2012 Sep; 167(3):555-62. PubMed ID: 22639874
[TBL] [Abstract][Full Text] [Related]
4. Stevens-Johnson syndrome and toxic epidermal necrolysis.
Harr T; French LE
Chem Immunol Allergy; 2012; 97():149-66. PubMed ID: 22613860
[TBL] [Abstract][Full Text] [Related]
5. Ophthalmic Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis and Relation to SCORTEN.
Morales ME; Purdue GF; Verity SM; Arnoldo BD; Blomquist PH
Am J Ophthalmol; 2010 Oct; 150(4):505-510.e1. PubMed ID: 20619392
[TBL] [Abstract][Full Text] [Related]
6. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel.
Halevy S; Ghislain PD; Mockenhaupt M; Fagot JP; Bouwes Bavinck JN; Sidoroff A; Naldi L; Dunant A; Viboud C; Roujeau JC;
J Am Acad Dermatol; 2008 Jan; 58(1):25-32. PubMed ID: 17919772
[TBL] [Abstract][Full Text] [Related]
7. 27 years of a single burn centre experience with Stevens-Johnson syndrome and toxic epidermal necrolysis: analysis of mortality risk for causative agents.
Weinand C; Xu W; Perbix W; Lefering R; Maegele M; Rathert M; Spilker G
Burns; 2013 Nov; 39(7):1449-55. PubMed ID: 23702222
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of histologic features of toxic epidermal necrolysis.
Valeyrie-Allanore L; Bastuji-Garin S; Guégan S; Ortonne N; Bagot M; Roujeau JC; Revuz JE; Wechsler J; Wolkenstein P
J Am Acad Dermatol; 2013 Feb; 68(2):e29-35. PubMed ID: 22088428
[TBL] [Abstract][Full Text] [Related]
9. Drug-induced Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS-TEN overlap: a multicentric retrospective study.
Barvaliya M; Sanmukhani J; Patel T; Paliwal N; Shah H; Tripathi C
J Postgrad Med; 2011; 57(2):115-9. PubMed ID: 21654132
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China.
Yang Y; Xu J; Li F; Zhu X
Int J Dermatol; 2009 Oct; 48(10):1122-8. PubMed ID: 19775409
[TBL] [Abstract][Full Text] [Related]
11. Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry.
Diphoorn J; Cazzaniga S; Gamba C; Schroeder J; Citterio A; Rivolta AL; Vighi GD; Naldi L;
Pharmacoepidemiol Drug Saf; 2016 Feb; 25(2):196-203. PubMed ID: 26687641
[TBL] [Abstract][Full Text] [Related]
12. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis.
Valeyrie-Allanore L; Wolkenstein P; Brochard L; Ortonne N; Maître B; Revuz J; Bagot M; Roujeau JC
Br J Dermatol; 2010 Oct; 163(4):847-53. PubMed ID: 20500799
[TBL] [Abstract][Full Text] [Related]
13. Toxic epidermal necrolysis and Stevens-Johnson syndrome in South Africa: a 3-year prospective study.
Kannenberg SM; Jordaan HF; Koegelenberg CF; Von Groote-Bidlingmaier F; Visser WI
QJM; 2012 Sep; 105(9):839-46. PubMed ID: 22543685
[TBL] [Abstract][Full Text] [Related]
14. Stevens-Johnson syndrome and toxic epidermal necrolysis in sub-Saharan Africa: a multicentric study in four countries.
Saka B; Barro-Traoré F; Atadokpédé FA; Kobangue L; Niamba PA; Adégbidi H; Yedomon HG; Traoré A; Pitché VP
Int J Dermatol; 2013 May; 52(5):575-9. PubMed ID: 23330601
[TBL] [Abstract][Full Text] [Related]
15. Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis.
Levi N; Bastuji-Garin S; Mockenhaupt M; Roujeau JC; Flahault A; Kelly JP; Martin E; Kaufman DW; Maison P
Pediatrics; 2009 Feb; 123(2):e297-304. PubMed ID: 19153164
[TBL] [Abstract][Full Text] [Related]
16. [Analysis of treatments and deceased cases of severe adverse drug reactions--analysis of 46 cases of Stevens-Johnson syndrome and toxic epidermal necrolysis].
Yamane Y; Aihara M; Tatewaki S; Matsukura S; Kanbara T; Yamakawa Y; Ikezawa Z
Arerugi; 2009 May; 58(5):537-47. PubMed ID: 19487835
[TBL] [Abstract][Full Text] [Related]
17. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients.
Chan HL; Stern RS; Arndt KA; Langlois J; Jick SS; Jick H; Walker AM
Arch Dermatol; 1990 Jan; 126(1):43-7. PubMed ID: 2404462
[TBL] [Abstract][Full Text] [Related]
18. A decade of burn unit experience with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: Clinical pathological diagnosis and risk factor awareness.
Lim VM; Do A; Berger TG; Nguyen AH; DeWeese J; Malone JD; Jordan K; Hom F; Tuffanelli L; Fillari P; Siu S; Grossman R
Burns; 2016 Jun; 42(4):836-43. PubMed ID: 26847613
[TBL] [Abstract][Full Text] [Related]
19. Profile and pattern of Stevens-Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: treatment outcomes.
Tan SK; Tay YK
Acta Derm Venereol; 2012 Jan; 92(1):62-6. PubMed ID: 21710108
[TBL] [Abstract][Full Text] [Related]
20. An epidemiological and clinical analysis of cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia.
Choon SE; Lai NM
Indian J Dermatol Venereol Leprol; 2012; 78(6):734-9. PubMed ID: 23075643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
